Orfadin

Orfadin is a brand name of nitisinone, approved by the FDA in the following formulation(s):

ORFADIN (nitisinone - capsule; oral)

• 
  Manufacturer: RARE DIS
  
  Approval date: January 18, 2002
  
  Strength(s): 10MG ^[RLD], 2MG, 5MG
  

Has a generic version of Orfadin been approved?

No. There is currently no therapeutically equivalent version of Orfadin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Orfadin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmaceutical compositions for the treatment of hereditary tyosinemia type I
  Patent 5,550,165
  Issued: August 27, 1996
  Inventor(s): Ellis; Martin K. & Lindstedt; Sven T. & Lock; Edward A. & Markstedt; Maj E. H. & Mutter; Linda C. & Prisbylla; Michael P.
  Assignee(s): Zeneca Limited
  The invention concerns novel pharmaceutical compositions containing as an active ingredient a 2-benzoyl-1,3-cyclohexanedione which is an inhibitor of the enzyme 4-hydroxyphenylpyruvate dioxygenase (HPPD). The compositions are valuable in the treating those disorders and diseases in which it is desirable to intervene in the metabolic sequences catalysed by HPPD, such as in treating tyrosinemia type I.
  
  Patent expiration dates:
  
  
  • August 27, 2013
    
  
  

See also...

• Orfadin Consumer Information (Wolters Kluwer)
• Orfadin Consumer Information (Cerner Multum)
• Orfadin Advanced Consumer Information (Micromedex)
• Nitisinone Consumer Information (Wolters Kluwer)
• Nitisinone Consumer Information (Cerner Multum)
• Nitisinone Advanced Consumer Information (Micromedex)